13 nov. L’hépatite virale constitue un problème de santé publique international, comparable à celui posé par d’autres grandes maladies transmissibles. VIH, hépatites virales et comorbidités: épidémiologie clinique et santé era: Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) CO3 . 29 nov. L’hépatite A est surveillée en France par la déclaration obligatoire . /Hepatites- virales/Hepatite-A/Comment-signaler-et-notifier-cette-maladie.
|Published (Last):||6 September 2011|
|PDF File Size:||19.94 Mb|
|ePub File Size:||3.83 Mb|
|Price:||Free* [*Free Regsitration Required]|
J Med Virol Can the “seek, test, treat, and retain” strategy viralss effective in France? Efficacy and tolerability of Etravirine in HIV-1 adult patients: Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study.
Impact on Tenofovir Ctrough but not on Renal Safety? Consequences on Chemotherapy Efficiency and Safety. Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIVinfected patients.
Clin J Am Soc Nephrol. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: What’s new in ? Antiretroviral exposure and comorbidities in an aging HIV-infected population: Risk factors of chronic kidney disease in HIV-infected patients.
Discussion:Hépatite virale — Wikipédia
Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, hepatits determinants of expensive drugs prescription. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Changes over the past 10 years in France. An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy.
Efficacy and safety of dolutegravir and rilpivirine dual therapy as 1 a simplification. Eur J Gastroenterol Hepatol. Acute and chronic hepatitis E in patients infected with human immunodeficiency virus.
Impact of tenofovir trough concentration. Br J Clin Pharmacol. Impact on tenofovir trough concentrations and renal safety.
Which antiretrovirals should be prescribed as first-line treatments? Case Rep Oncol Med. A Cross- Sectional Analysis. Clin Res Hepatol Gastroenterol. HIV is associated with airway obstruction: Eur J Clin Pharmacol. Linked in Viadeo Youtube Email.
Agence Nationale de Recherches Sur le SIDA et les hepatites virales
Tipranavir in highly antiretroviral treatment-experienced patients: Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: The spectrum of malignancies in HIV-infected patients in in France: Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: Results of a large French prospective cohort.
Risk factors associated with overweight and obesity in HIV-infected people: Renal impairment girales patients receiving a tenofovir-cART regimen: Formulaire de recherche Recherche. The challenge of geriatric patients.
Frailty in HIV infected people: Facebook Twitter Google Plus fr en du ar it sp. Cancer risk in HIV-infected patients: Effectiveness and tolerance of single tablet versus once hepatitess multiple tablet regimens as first-line antiretroviral therapy – Results from a large french multicenter cohort study.
Results from a French prospective cohort. J Acquir Immune Defic Syndr. Infection par le VIH et parcours de soin: Mandibular osteonecrosis and dental exfoliation after trigeminal zoster in an HIV-infected patient.
HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
Scand J Infect Dis. No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in Hepattites.
C Med Mal Infect. Aging, behavioral factors but not cART in a cross-sectional study. From guidelines to viraoes practice. Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.